ASB 17061

Drug Profile

ASB 17061

Alternative Names: ASB-17061

Latest Information Update: 27 May 2014

Price : $50

At a glance

  • Originator Asubio Pharmaceuticals
  • Class Skin disorder therapies
  • Mechanism of Action Chymase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atopic dermatitis

Most Recent Events

  • 27 May 2014 Discontinued - Phase-II for Atopic dermatitis in USA (PO)
  • 01 Jan 2014 Asubio Pharmaceuticals completes a phase II trial in Atopic dermatitis in USA (NCT01756898)
  • 25 Nov 2013 Asubio Pharmaceuticals completes enrolment in its phase II trial for Atopic dermatitis in USA (NCT01756898)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top